Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Saint-Benoit – page 8

190 clinical trials in Saint-Benoit, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Benoit at a glance
190
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

190 trials in Saint-Benoit

Open in trial search

Transitional cell carcinoma

Not yet recruiting

Neoadjuvant Study of Avelumab with Gemcitabine and Cisplatin versus Chemotherapy Alone in Patients with High‑Grade Localized Upper Tract Urothelial Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Reducing abemaciclib, palbociclib and ribociclib after complete response in HER2‑negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Pneumonia+1

Not yet recruiting

Early Use of Dexamethasone versus Sodium Chloride Placebo in Patients with Severe Influenza-Induced Acute Hypoxemic Respiratory Failure (Phase III Randomized Trial)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospital Region Metz Thionville

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:French Innovative Leukemia Organization

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Pyelonephritis

Not yet recruiting

Fosfomycin trometamol versus drug combination for treating acute E. coli pyelonephritis in women aged 75 years and older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Amikacin Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Centre Hospitalier De Versailles

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Plasma cell myeloma

Not yet recruiting

A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Other cities in France

The busiest research cities in the country

All 376 cities in France
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.